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oThe causes of the BCR-ABL protein formation are still unknown, but the 
effects of the oncoprotein on cell’s stability have been extensively studied.  
oThe deregulation of the protein produces high cell proliferation, telomere 
shortening, ROS, DNA damage and disruption of DNA repair mechanisms. 
Altogether, these factors might induce genomic instability. 
oCML cells in their early stages may “activate” ALT as a telomere maintaining 
mechanism. Through the acquisition of additional chromosomal aberrations 
telomerase might be activated and become the predominant mechanism.  
oTaking all these data together, an appropriate strategy of treatment could be 
the supply of TKIs and antioxidant drugs to CML patients in the early stages of 
the disease.  
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Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by a high proliferation 
and massive accumulation of myeloid cells that retain their ability to differentiate. It is mainly caused 
by the fusion protein BCR-ABL which disrupts the normal cell cycle.  
Telomeres are specialized structures which are found at the end of eukaryotic chromosomes. They 
are involved in the protection against genetic information loss, prevention of end-to-end fusions, 
senescence and apoptosis.   
OBJECTIVES 
CML, like many cancers, is characterized by a telomere shortening. The aim of this review is to 
discuss this shortening and how it affects cells that display it. On the other hand, due to the 
discordance among researchers, the relationship between the oncogenic protein and the telomerase 
is going to be discussed.  
INTRODUCTION 
Figure 1.  The Web site of the National Cancer Institute (http://www.cancer.gov) 
Figure 2. en.wikipedia.org/wiki/Imatinib 
THE FUSION GENE  
On the left side of the diagram there is the reciprocal translocation t(9;22)(q34;q11.2) which results in the formation of the 
Philadelphia chromosome. This chromosome carries the BCR-Abl gene, which codes for the BCR-ABL protein. On the right 
side of the diagram there is the gene product (green) with Imatinib, a tyrosine kinase inhibitor (TKI), in red.  
The oncogenic protein BCR-ABL has many important roles in the progression 
through the three phases of the disease (chronic, advanced and blast crisis). 
These roles include the stimulation of signaling pathways that induce growth 
independently of the presence of growth factors, apoptosis inhibition, regulation of 
cell adhesion and tissue invasion, modulation of DNA damage responses and 
genomic instability, among others. Red arrows indicate inhibition and black arrows 
indicate activation of cell factors.  
BCR-ABL AND ITS EFFECTS ON CELL’S STABILITY 
 
 
 
Probably, the most important factor 
involved in the chronic phase – blast 
crisis transition. It is mainly due to: 
 
Reactive oxygen species (ROS)  
Unfaithful/inefficient DNA damage repair 
Telomere shortening 
ROS may induce single and double strand breaks in DNA. These 
damages can be fixed by several DNA repair mechanisms such as 
BER, NER, HRR, MMR, etc. However, if damages are not properly 
repaired, because of the inefficiency of repair pathways, they can lead 
to genomic instability.  
The overproduction of ROS, the high tax of cell proliferation and the 
disruption of shelterines may lead to telomere erosion. Despite there is 
a general telomere shortening, some chromosomes may show a 
telomere lengthening on specific arms. Red bars indicate telomere 
shortening and yellow bars indicate telomere lengthening. The 
chromosome number is on the x-axis and the percentage of cases is on 
the y-axis.  
Figure 5. Samassekou, O., et al. (2009). Individual telomere lengths in chronic myeloid leukemia. Neoplasia, 11(11), 1146–1154. 
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MECHANISMS OF TELOMERE MAINTENANCE 
Several projects have aimed to shed light on the relationship between telomerase 
and the BCR-ABL protein. Some scientists have found that the oncoprotein 
upregulates hTERT gene expression. However, other researchers have found that 
the BCR-ABL protein downregulates telomerase activity by inhibiting hTERT gene 
expression. In addition, the possibility of an alternative lengthening of telomeres 
(ALT) has also been proposed.  
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CONCLUDING REMARKS 
Figure 7. Modified from Townsley, D.M. et al., (2014). Bone 
marrow failure and telomeropathies. Blood ;124 (18) 2775-2783. 
Figure 3. Modified from Danilo Perrotti, et al. (2010) . Chronic myeloid leukemia: mechanisms of blastic transformation. Journal of Clinical 
Investigation;120(7):2254-2264.  
Cellular senescence, crisis and telomerase activation. Somatic 
cells display telomere shortening in each cell division until they 
reach senescence. However, some cells might develop 
mechanisms to avoid this. Cell doublings are on the x-axis and 
telomere length is on the y-axis. The blue arrow shows the 
telomerase activity in germ cells. The black arrow shows the 
telomerase activity in the other cells.  
Figure 4. Danilo Perrotti, et al. (2010) . Chronic myeloid leukemia: mechanisms of blastic transformation. Journal of Clinical 
Investigation;120(7):2254-2264.  
Figure 6. what-when-how.com  
Suggested model for telomere maintenance in CML. Blue circles are cells using 
ALT. Red circles are cells using telomerase. Brown circles are cells expressing 
high telomerase activity and resistance to Imatinib.  
Figure 8. Samassekou, O. (2013). Dynamic length changes of 
telomeres and their nuclear organization in chronic myeloid 
leukemia. Cancers, 5(3), 1086–1102.  
